Da Volterra is looking forward to being on air with the C. Diff Foundation on their radio show, C. diff Spores and More on Tuesday, July 24th at 1PM ET/7PM CET. Our CSO, Jean de Gunzburg will discuss with the C.Diff Foundation‘s Nancy Caralla about DAV132.
The show is entitled: Recent Publications on DAV132: Microbiota Protection and Prevention of CDI
You can listen live or listen to the podcast at a later date at the link.
About Da Volterra:
Da Volterra is developing a pipeline of assets for protection of the intestinal microbiome with antibiotic treatments. Our most advanced asset, DAV132 has demonstrated excellent safety in four Phase 1 clinical trials and is currently in Phase 2. Da Volterra is working to protect the intestinal microbiome for optimal health, prevent devastating Clostridium difficile infections and combat antibiotic resistance.
About Jean de Gunzburg – PhD, Chief Scientific Officer
Jean de Gunzburg obtained his Ph.D. from the University of Paris 7 for his work at the Institut Pasteur in Paris, followed by a postdoctoral training at the Whitehead Institute for Biomedical Research (Cambridge). In 1998 he became the Research Director at the CNRS and headed the Laboratory for Signal Transduction and Oncogenesis of Inserm at the Institut Curie. After a successful academic career and having published over 70 articles in international journals Jean is now devoted to advancing scientific and drug development at Da Volterra.